Spark Therapeutics (ONCE) Reports Q1 Loss of $1.70/Share

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. WCN
6. SPOT
7. BMY
8. SPY
9. FIX
10. TSCO

Go back to Spark Therapeutics (ONCE) Reports Q1 Loss of $1.70/Share

Spark Therapeutics Reports First Quarter 2017 Financial Results and Recent Business Progress

May 9, 2017 7:30 AM EDT

Work on U.S. Biologics License Application (BLA) for investigational voretigene neparvovec is complete

Interim results from SPK-7001 Phase 1/2 clinical trial in choroideremia reported; continuing enrollment targeting participants at earlier stage of disease

PHILADELPHIA, May 09, 2017 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ: ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, today announced financial results for the first quarter of 2017 and recent business progress.

Im pleased to announce that our work on the rolling BLA for voretigene neparvovec for... More